New Therapies Offer Hope for HER2-Positive Breast Cancer Patients with Brain Metastases
For patients with HER2-positive (human epidermal growth factor receptor 2-positive) breast cancer who develop brain metastases, new systemic therapies are showing promise, offering improved outcomes and a shift in treatment paradigms. Historically, brain metastases signaled a poor prognosis, but advancements in targeted therapies are changing this landscape.
The Challenge of Brain Metastases in HER2-Positive Breast Cancer
Brain metastases occur in up to 30–50% of patients with breast cancer [1], and are particularly difficult to treat due to the blood-brain barrier (BBB). The BBB is a protective mechanism that limits the entry of many drugs into the brain, hindering the effectiveness of systemic treatments.
Targeting HER2 and Overcoming the Blood-Brain Barrier
Recent research focuses on therapies that specifically target HER2 and can effectively penetrate the BBB. Several tyrosine kinase inhibitors (TKIs) – lapatinib, neratinib, and tucatinib – are now recommended in combination with monoclonal antibodies or chemotherapy drugs [2]. Antibody-drug conjugates (ADCs) like trastuzumab-deruxtecan and trastuzumab-emtansine are also being utilized.
New Treatment Approaches and Clinical Trials
As of December 15, 2024, understanding how drugs cross the blood-brain barrier remains a critical unmet medical need [2]. Clinical trials, such as NCT03714243, are investigating methods to disrupt the blood-brain barrier using magnetic resonance-guided focused ultrasound (MRgFUS) to enhance drug delivery in HER2-positive breast cancer brain metastases [4].
Systemic Therapies Preferred in Select Cases
Data presented on March 8, 2025, indicates that systemic therapies are now preferred in some patients with HER2-positive breast cancer and brain metastases [3], reflecting the growing efficacy of these targeted approaches.
Looking Ahead
The development of therapies that can effectively target HER2 and overcome the challenges posed by the blood-brain barrier represents a significant step forward in the treatment of HER2-positive breast cancer with brain metastases. Ongoing research and clinical trials continue to refine these approaches and offer hope for improved outcomes and quality of life for patients facing this complex disease.